|
1
|
Bruix J, Reig M and Sherman M:
Evidence-based diagnosis, staging, and treatment of patients with
hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maluccio M and Covey A: Recent progress in
understanding, diagnosing, and treating hepatocellular carcinoma.
CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singal AG, Pillai A and Tiro J: Early
detection, curative treatment, and survival rates for
hepatocellular carcinoma surveillance in patients with cirrhosis: a
meta-analysis. PLoS Med. 11:e10016242014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guan DX, Shi J, Zhang Y, Zhao JS, Long LY,
Chen TW, Zhang EB, Feng YY, Bao WD, Deng YZ, et al: Sorafenib
enriches epithelial cell adhesion molecule-positive tumor
initiating cells and exacerbates a subtype of hepatocellular
carcinoma through TSC2-AKT cascade. Hepatology. 62:1791–1803. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma JL, Zeng S, Zhang Y, Deng GL and Shen
H: Epithelial-mesenchymal transition plays a critical role in drug
resistance of hepatocellular carcinoma cells to oxaliplatin. Tumour
Biol. 37:6177–6184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bertran E, Crosas-Molist E, Sancho P, Caja
L, Lopez-Luque J, Navarro E, Egea G, Lastra R, Serrano T, Ramos E
and Fabregat I: Overactivation of the TGF-β pathway confers a
mesenchymal-like phenotype and CXCR4-dependent migratory properties
to liver tumor cells. Hepatology. 58:2032–2044. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fuzer AM, Filho JC, Becceneri AB, Dos
Santos DA, da Silva MF, Vieira PC, Fernandes JB, Selistre-de-Araujo
HS, Cazal CM and Cominetti MR: Effects of limonoid cedrelone on
MDA-MB-231 breast tumor cells in vitro. Anticancer Agents Med Chem.
13:1645–1653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gopalakrishnan G, Pradeep Singh ND,
Kasinath V, Malathi R and Rajan SS: Photooxidation of cedrelone, a
tetranortriterpenoid from Toona ciliata. Photochem Photobiol.
72:464–466. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li A, Yan Q, Zhao X, Zhong J, Yang H, Feng
Z, Du Y, Wang Y, Wang Z, Wang H, et al: Decreased expression of
PBLD correlates with poor prognosis and functions as a tumor
suppressor in human hepatocellular carcinoma. Oncotarget.
7:524–537. 2016.PubMed/NCBI
|
|
10
|
Long J, Lang ZW, Wang HG, Wang TL, Wang BE
and Liu SQ: Glutamine synthetase as an early marker for
hepatocellular carcinoma based on proteomic analysis of resected
small hepatocellular carcinomas. Hepatobiliary Pancreat Dis Int.
9:296–305. 2010.PubMed/NCBI
|
|
11
|
Li D, Zhang J, Xi Y, Zhang L, Li W, Cui J,
Xing R, Pan Y, Pan Z, Li F and Lu Y: Mitogen-activated protein
kinase activator with WD40 repeats (MAWD) and MAWD-binding protein
induce cell differentiation in gastric cancer. BMC Cancer.
15:6372015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
European Association For The Study Of The
Liver1; European Organisation For Research And Treatment Of Cancer,
. EASL-EORTC clinical practice guidelines: management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: a study of 100 cases among 48,900
necropsies. Cancer. 7.462–503. 1954.
|
|
14
|
Zhao X, Fan J, Zhi F, Li A, Li C, Berger
AE, Boorgula MP, Barkataki S, Courneya JP, Chen Y, et al:
Mobilization of epithelial mesenchymal transition genes
distinguishes active from inactive lesional tissue in patients with
ulcerative colitis. Hum Mol Genet. 24:4615–4624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giongo AM, Vendramim JD, Freitas SD and
Silva MF: Toxicity of secondary metabolites from meliaceae against
Spodoptera frugiperda (J. E. Smith) (Lepidoptera: Noctuidae).
Neotrop Entomol. 45:725–733. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cazal CM, Choosang K, Severino VG, Soares
MS, Sarria AL, Fernandes JB, Silva MF, Vieira PC, Pakkong P,
Almeida GM, et al: Evaluation of effect of triterpenes and
limonoids on cell growth, cell cycle and apoptosis in human tumor
cell line. Anticancer Agents Med Chem. 10:769–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iriyama C, Matsuda S, Katsumata R and
Hamaguchi M: Cloning and sequencing of a novel human gene which
encodes a putative hydroxylase. J Hum Genet. 46:289–292. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Katrinli S, Ozdil K, Sahin A, Ozturk O,
Kir G, Baykal AT, Akgun E, Sarac OS, Sokmen M, Doğanay HL, et al:
Proteomic profiling of HBV infected liver biopsies with different
fibrotic stages. Proteome Sci. 15:72017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Margini C and Dufour JF: The story of HCC
in NAFLD: from epidemiology, across pathogenesis, to prevention and
treatment. Liver Int. 36:317–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Minicis S, Day C and Svegliati-Baroni
G: From NAFLD to NASH and HCC: pathogenetic mechanisms and
therapeutic insights. Curr Pharm Des. 19:5239–5249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pincus MR, Fenelus M, Sarafraz-Yazdi E,
Adler V, Bowne W and Michl J: Anti-cancer peptides from ras-p21 and
p53 proteins. Curr Pharm Des. 17:2677–2698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Singh H, Longo DL and Chabner BA:
Improving prospects for Targeting RAS. J Clin Oncol. 33:3650–3659.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hobbs GA, Der CJ and Rossman KL: RAS
isoforms and mutations in cancer at a glance. J Cell Sci.
129:1287–1292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Banerjee A, Jang H, Nussinov R and
Gaponenko V: The disordered hypervariable region and the folded
catalytic domain of oncogenic K-Ras4B partner in phospholipid
binding. Curr Opin Struct Biol. 36:10–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sammoud S, Khiari M, Semeh A, Amine L,
Ines C, Amira A, Lilia K, Taher K, Sabeh M and Saadia B:
Relationship between expression of ras p21 oncoprotein and mutation
status of the K-ras gene in sporadic colorectal cancer patients in
Tunisia. Appl Immunohistochem Mol Morphol. 20:146–152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lv C, Hong Y, Miao L, Li C, Xu G, Wei S,
Wang B, Huang C and Jiao B: Wentilactone A as a novel potential
antitumor agent induces apoptosis and G2/M arrest of human lung
carcinoma cells, and is mediated by HRas-GTP accumulation to
excessively activate the Ras/Raf/ERK/p53-p21 pathway. Cell Death
Dis. 4:e9522013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Z, Ali S, Banerjee S, Bao B, Li Y,
Azmi AS, Korc M and Sarkar FH: Activated K-Ras and INK4a/Arf
deficiency promote aggressiveness of pancreatic cancer by induction
of EMT consistent with cancer stem cell phenotype. J Cell Physiol.
228:556–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chrzanowska-Wodnicka M: Distinct functions
for Rap1 signaling in vascular morphogenesis and dysfunction. Exp
Cell Res. 319:2350–2359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Banerjee R, Russo N, Liu M, Van Tubergen E
and D'Silva NJ: Rap1 and its regulatory proteins: the tumor
suppressor, oncogene, tumor suppressor gene axis in head and neck
cancer. Small GTPases. 3:192–197. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li Z, Liu XB, Liu YH, Xue YX, Wang P, Liu
LB, Yao YL and Ma J: Functions for the cAMP/Epac/Rap1 signaling
pathway in low-dose endothelial monocyte-activating
Polypeptide-II–Induced opening of blood-tumor barrier. J Mol
Neurosci. 57:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tamate M, Tanaka R, Osogami H, Matsuura M,
Satohisa S, Iwasaki M and Saito T: Rap1GAP inhibits tumor
progression in endometrial cancer. Biochem Biophys Res Commun.
485:476–483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang Y, Zhang J, Yan Y, Cai H, Li M, Sun
K, Wang J, Liu X, Wang J and Duan X: Low expression of Rap1GAP is
associated with epithelial-mesenchymal transition (EMT) and poor
prognosis in gastric cancer. Oncotarget. 8:8057–8068.
2017.PubMed/NCBI
|
|
35
|
Wang SF, Aoki M, Nakashima Y, Shinozuka Y,
Tanaka H, Taniwaki M, Hattori M and Minato N: Development of
Notch-dependent T-cell leukemia by deregulated Rap1 signaling.
Blood. 111:2878–2886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Priego N, Arechederra M, Sequera C,
Bragado P, Vázquez-Carballo A, Gutiérrez-Uzquiza Á, Martín-Granado
V, Ventura JJ, Kazanietz MG, Guerrero C and Porras A: C3G
knock-down enhances migration and invasion by increasing
Rap1--mediated p38α activation, while it impairs tumor growth
through p38α--independent mechanisms. Oncotarget. 7:45060–45078.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsygankova OM, Wang H and Meinkoth JL:
Tumor cell migration and invasion are enhanced by depletion of Rap1
GTPase-activating protein (Rap1GAP). J Biol Chem. 288:24636–24646.
2013. View Article : Google Scholar : PubMed/NCBI
|
